![Biomedicines | Free Full-Text | Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis Biomedicines | Free Full-Text | Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis](https://www.mdpi.com/biomedicines/biomedicines-10-00316/article_deploy/html/images/biomedicines-10-00316-g001-550.jpg)
Biomedicines | Free Full-Text | Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis
![Systemic Sclerosis - Musculoskeletal and Connective Tissue Disorders - Merck Manuals Professional Edition Systemic Sclerosis - Musculoskeletal and Connective Tissue Disorders - Merck Manuals Professional Edition](https://www.merckmanuals.com/-/media/manual/professional/images/s/y/s/systemic_sclerosis_hand_high.jpg?thn=0&sc_lang=en)
Systemic Sclerosis - Musculoskeletal and Connective Tissue Disorders - Merck Manuals Professional Edition
![Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China | Arthritis Research & Therapy | Full Text Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China | Arthritis Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-018-1735-4/MediaObjects/13075_2018_1735_Fig1_HTML.png)
Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China | Arthritis Research & Therapy | Full Text
![Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort | Arthritis Research & Therapy | Full Text Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort | Arthritis Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-020-2140-3/MediaObjects/13075_2020_2140_Fig1_HTML.png)
Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort | Arthritis Research & Therapy | Full Text
![Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature | Arthritis Research & Therapy | Full Text Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature | Arthritis Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-019-1867-1/MediaObjects/13075_2019_1867_Fig2_HTML.png)
Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature | Arthritis Research & Therapy | Full Text
![Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China | Arthritis Research & Therapy | Full Text Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China | Arthritis Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-018-1735-4/MediaObjects/13075_2018_1735_Fig2_HTML.png)
Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China | Arthritis Research & Therapy | Full Text
![Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality | Arthritis Research & Therapy | Full Text Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality | Arthritis Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-021-02672-y/MediaObjects/13075_2021_2672_Fig3_HTML.png)